Source comparison
Best TB-500 Dosage Endurance 2026: Protocol Comparison
| Protocol Phase | Dose per Injection | Injection Frequency | Duration | Plasma TB-4 Range (est.) | Primary Outcome Target | Bottom Line ||—|—|—|—|—|—|| Loading Phase (Standard) | 2.5mg | Twice weekly (e.g., Mon/Thu) | 4–6 weeks | 40–60 ng/mL | Capillary densi
This comparison does not assign a generated winner or score.
- | Protocol Phase | Dose per Injection | Injection Frequency | Duration | Plasma TB-4 Range (est.) | Primary Outcome Target | Bottom Line ||—|—|—|—|—|—|| Loading Phase (Standard) | 2.5mg | Twice weekly (e.g., Mon/Thu) | 4–6 weeks | 40–60 ng/mL | Capillary density increase, VO2max improvement | Gold standard for most endurance models. Balances efficacy and peptide cost || Loading Phase (High-Dose) | 5mg | Twice weekly | 4–6 weeks | 60–85 ng/mL | Same as standard | Marginal benefit over 2.5mg; ceiling effect observed in multiple studies || Maintenance Phase | 2mg | Once weekly | 8–12 weeks | 25–40 ng/mL | Sustain vascular adaptations from loading | Required to maintain capillary-to-fiber ratio gains post-loading || Acute Loading (Flawed) | 10mg | Once weekly | 4 weeks | Highly variable (peaks/troughs) | Same as standard | Inconsistent plasma levels. Not recommended for endurance research || Low-Dose Continuous | 1mg | Twice weekly | 12 weeks | 15–30 ng/mL | Incremental endurance gain | Be